(Total Views: 480)
Posted On: 04/07/2020 11:17:07 AM
Post# of 149091
Zuess,
Absolutely !!!
Few days back I posted some information in regards to IL-6 and CAP (community acquired Pneumonia) and the similarities with COVID symptoms . Also, some facts about Pneumonia regarding the extension of the condition.
Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073574/
It Leronlimab works with COVID it will work with Pneumonia big time. My quote then:
And the market, as you point out, is HUGE.
Absolutely !!!
Few days back I posted some information in regards to IL-6 and CAP (community acquired Pneumonia) and the similarities with COVID symptoms . Also, some facts about Pneumonia regarding the extension of the condition.
Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073574/
It Leronlimab works with COVID it will work with Pneumonia big time. My quote then:
Quote:
Bottom line: for CAP the levels of IL-6 predict the mortality rate pretty damn well. If this is the case for COVID as well (until today, I don’t think anybody knows this for certain) the reduction of 70% on IL-6 achieved by Leronlimab is a life saver with no questions about it. It would be nice to learn to what level these values where reduced (a normal male has a value of 0 – 3.5 pg/ml in plasma).
And the market, as you point out, is HUGE.
(5)
(0)Scroll down for more posts ▼
